peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Medical publishes the Annual Report for 2016

26 Apr 2017, 07:58
Regulatory information

The Auditor’s report contains a remark that the company has failed on several occasions to perform its obligations to make timely payments of taxes and fees. At the end of the fiscal year there was no deficit on the tax account.

Authorized Public Accountants, Dan Kjellqvist and Jonas Nihlberg, in Hansa Medical AB, recommend to the general meeting of shareholders that the members of the Board of Directors and the Managing Director be discharged from liability for the past financial year.

In 2016, procedures for paying taxes and fees have been handled by an external accounting firm and the procedures have been inadequate. From 2017, these routines will be managed internally in the company to prevent the error from occurring again.

Hansa Medical's Annual Report for 2016 is now available on the company’s website,

The Annual Report is posted to shareholders and other stakeholders who specifically request it. For further information please contact the company by telephone +46 46-16 56 70 or e-mail 

The information in this press release is disclosed pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the contact person stated below on April 26, 2017 at 08.00 CET.

For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: 46 70-633 30 42

Hansa Medical in brief
Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead project IdeS is a proprietary antibody-degrading enzyme currently in late- stage clinical development for kidney transplant patients,
with significant potential for further development in other solid organ transplants and a wide range of acute autoimmune indications. The company also has a strong pipeline of preclinical assets that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin cleaving enzymes are developed for repeat dosing translating the Hansa Medical technology into relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden, its shares (ticker: HMED) are listed on Nasdaq Stockholm.